Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Shares Outstanding (Weighted Average) (2016 - 2025)

Guided Therapeutics' Shares Outstanding (Weighted Average) history spans 16 years, with the latest figure at $76.4 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 36.52% year-over-year to $76.4 million; the TTM value through Sep 2025 reached $76.4 million, up 36.52%, while the annual FY2024 figure was $57.3 million, 12.14% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $76.4 million at Guided Therapeutics, up from $73.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $76.4 million in Q3 2025 and bottomed at $49297.0 in Q1 2023.
  • The 5-year median for Shares Outstanding (Weighted Average) is $50.1 million (2023), against an average of $40.1 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) surged 262656.83% in 2021 before it crashed 99.76% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $13.4 million in 2021, then skyrocketed by 142.99% to $32.5 million in 2022, then skyrocketed by 57.3% to $51.1 million in 2023, then grew by 12.14% to $57.3 million in 2024, then surged by 33.16% to $76.4 million in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Shares Outstanding (Weighted Average) are $76.4 million (Q3 2025), $73.6 million (Q2 2025), and $68.3 million (Q1 2025).